Ligand Pharms Glucagon
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more
Ligand Pharms Glucagon (LGNXZ) - Net Assets
Latest net assets as of June 2025: $828.53 Million USD
Based on the latest financial reports, Ligand Pharms Glucagon (LGNXZ) has net assets worth $828.53 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($948.60 Million) and total liabilities ($120.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $828.53 Million |
| % of Total Assets | 87.34% |
| Annual Growth Rate | N/A |
| 5-Year Change | 17.04% |
| 10-Year Change | 249.98% |
| Growth Volatility | 240.73 |
Ligand Pharms Glucagon - Net Assets Trend (2002–2024)
This chart illustrates how Ligand Pharms Glucagon's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ligand Pharms Glucagon (2002–2024)
The table below shows the annual net assets of Ligand Pharms Glucagon from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $830.44 Million | +18.48% |
| 2023-12-31 | $700.91 Million | +17.31% |
| 2022-12-31 | $597.49 Million | -27.24% |
| 2021-12-31 | $821.16 Million | +15.73% |
| 2020-12-31 | $709.52 Million | -7.52% |
| 2019-12-31 | $767.23 Million | +36.78% |
| 2018-12-31 | $560.91 Million | +40.30% |
| 2017-12-31 | $399.79 Million | +17.14% |
| 2016-12-31 | $341.29 Million | +43.83% |
| 2015-12-31 | $237.28 Million | +872.15% |
| 2014-12-31 | $24.41 Million | -50.80% |
| 2013-12-31 | $49.61 Million | +87.32% |
| 2012-12-31 | $26.48 Million | +55.89% |
| 2011-12-31 | $16.99 Million | +386.12% |
| 2010-12-31 | $3.50 Million | -71.09% |
| 2009-12-31 | $12.09 Million | +510.51% |
| 2008-12-31 | $1.98 Million | -95.22% |
| 2007-12-31 | $41.46 Million | +4.44% |
| 2006-12-31 | $39.70 Million | +115.43% |
| 2005-12-31 | $-257.24 Million | -200.62% |
| 2003-12-31 | $255.67 Million | +669.63% |
| 2002-12-31 | $-44.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ligand Pharms Glucagon's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 49898400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $498.98 Million | 60.09% |
| Common Stock | $20.00K | 0.00% |
| Other Comprehensive Income | $-5.94 Million | -0.72% |
| Other Components | $337.38 Million | 40.63% |
| Total Equity | $830.44 Million | 100.00% |
Ligand Pharms Glucagon Competitors by Market Cap
The table below lists competitors of Ligand Pharms Glucagon ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BLOOBER TEAM ZY-01
F:6BO
|
$56.59K |
|
TOTS3F
SA:TOTS3F
|
$56.68K |
|
FERRAGAMO - Dusseldorf Stock Exchang
DU:S9L
|
$56.73K |
|
Cerillion PLC
LSE:CER
|
$56.78K |
|
Florence One Capital Inc.
V:FONC-P
|
$56.57K |
|
Edel AG
HM:EDL
|
$56.53K |
|
Namkwang Engineering & Construction Co. Ltd.
KQ:001260
|
$56.47K |
|
Gloo Holdings, Inc. Class A Common Stock
NASDAQ:GLOO
|
$56.38K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ligand Pharms Glucagon's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 700,913,000 to 830,439,000, a change of 129,526,000 (18.5%).
- Net income of 9,068,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 5,125,000.
- Other factors increased equity by 125,583,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $9.07 Million | +1.09% |
| Other Comprehensive Income | $-5.12 Million | -0.62% |
| Other Changes | $125.58 Million | +15.12% |
| Total Change | $- | 18.48% |
Book Value vs Market Value Analysis
This analysis compares Ligand Pharms Glucagon's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $0.00 | $0.00 | x |
| 2003-12-31 | $0.00 | $0.00 | x |
| 2005-12-31 | $0.00 | $0.00 | x |
| 2006-12-31 | $0.00 | $0.00 | x |
| 2007-12-31 | $0.00 | $0.00 | x |
| 2008-12-31 | $0.00 | $0.00 | x |
| 2009-12-31 | $0.00 | $0.00 | x |
| 2010-12-31 | $0.00 | $0.00 | x |
| 2011-12-31 | $0.00 | $0.00 | x |
| 2012-12-31 | $0.00 | $0.00 | x |
| 2013-12-31 | $0.00 | $0.00 | x |
| 2014-12-31 | $0.00 | $0.00 | x |
| 2015-12-31 | $11.18 | $0.00 | x |
| 2016-12-31 | $16.38 | $0.00 | x |
| 2017-12-31 | $17.03 | $0.00 | x |
| 2018-12-31 | $23.31 | $0.00 | x |
| 2019-12-31 | $38.83 | $0.00 | x |
| 2020-12-31 | $43.84 | $0.00 | x |
| 2021-12-31 | $47.61 | $0.00 | x |
| 2022-12-31 | $35.42 | $0.00 | x |
| 2023-12-31 | $39.47 | $0.00 | x |
| 2024-12-31 | $45.40 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ligand Pharms Glucagon utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.43%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.13x
- Recent ROE (1.09%) is below the historical average (16.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | -33.73% | 0.00x | 0.00x | $-28.11 Million |
| 2003 | -14.65% | -26.54% | 0.53x | 1.04x | $-63.03 Million |
| 2005 | 0.00% | -118.93% | 0.52x | 0.00x | $-70.75 Million |
| 2006 | -777.59% | -150.88% | 0.43x | 11.92x | $-215.42 Million |
| 2007 | 967.50% | 2184.64% | 0.07x | 5.95x | $278.78 Million |
| 2008 | 0.00% | -359.19% | 0.16x | 0.00x | $-97.08 Million |
| 2009 | -52.03% | -5.00% | 0.27x | 37.88x | $-2.32 Million |
| 2010 | 0.00% | -44.07% | 0.31x | 0.00x | $-9.89 Million |
| 2011 | 117.70% | 33.88% | 0.25x | 14.15x | $9.31 Million |
| 2012 | -8.90% | -7.51% | 0.30x | 3.94x | $-5.00 Million |
| 2013 | 23.02% | 23.32% | 0.47x | 2.11x | $6.46 Million |
| 2014 | 44.50% | 18.15% | 0.25x | 9.80x | $9.08 Million |
| 2015 | -77.66% | -256.23% | 0.14x | 2.12x | $-208.00 Million |
| 2016 | 5.36% | 16.78% | 0.18x | 1.76x | $-15.84 Million |
| 2017 | 25.49% | 72.22% | 0.20x | 1.81x | $61.93 Million |
| 2018 | 25.55% | 57.00% | 0.19x | 2.34x | $87.23 Million |
| 2019 | 82.02% | 523.19% | 0.08x | 1.95x | $552.58 Million |
| 2020 | -0.42% | -1.60% | 0.14x | 1.92x | $-73.94 Million |
| 2021 | 6.96% | 23.66% | 0.19x | 1.58x | $-24.98 Million |
| 2022 | -5.58% | -17.00% | 0.26x | 1.28x | $-93.11 Million |
| 2023 | 7.44% | 39.72% | 0.17x | 1.12x | $-17.94 Million |
| 2024 | 1.09% | 5.43% | 0.18x | 1.13x | $-73.98 Million |
Industry Comparison
This section compares Ligand Pharms Glucagon's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ligand Pharms Glucagon (LGNXZ) | $828.53 Million | 0.00% | 0.14x | $56.58K |
| Abcam plc (ABCZF) | $726.90 Million | -1.17% | 0.45x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $11.42 Million | 85.41% | 3.81x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.25 Million |
| Adamas Trust, Inc. (ADAMG) | $2.43 Billion | 7.94% | 1.33x | $2.09 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $33.92 Million | -162.39% | 2.67x | $10.06 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $5.32 Million | -457.58% | 45.29x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $282.84 Million | 1.97% | 0.05x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $4.04 Billion | 10.04% | 0.29x | $112.87K |
| Alvotech Warrant (ALVOW) | $-564.42 Million | 0.00% | 0.00x | $35.01 Million |